



General Assembly

February Session, 2020

**Raised Bill No. 145**

LCO No. 1396



Referred to Committee on PUBLIC HEALTH

Introduced by:  
(PH)

**AN ACT REQUIRING PHARMACIES TO MAKE MANUFACTURER  
REBATES FOR PRESCRIPTION DRUGS AVAILABLE TO PATIENTS.**

Be it enacted by the Senate and House of Representatives in General  
Assembly convened:

1 Section 1. (NEW) (*Effective October 1, 2020*) (a) As used in this section:

2 (1) "Prescription drug" has the same meaning as provided in section  
3 19a-754b of the general statutes;

4 (2) "Pharmacy" has the same meaning as provided in section 20-571  
5 of the general statutes; and

6 (3) "Rebate" means a discount or concession, which affects the price  
7 of an outpatient prescription drug, that a pharmaceutical manufacturer  
8 directly provides to a pharmacy or a pharmacist for an outpatient  
9 prescription drug manufactured by the pharmaceutical manufacturer  
10 and dispensed by the pharmacy or pharmacist; and "rebate" does not  
11 include a bona fide service fee, as defined in 42 CFR 447.502, as amended  
12 from time to time.

13 (b) Each pharmacy and pharmacist shall make rebates available to

14 patients at the point of purchase by a patient of an outpatient  
15 prescription drug. No pharmacy or pharmacist may retain any savings  
16 on the cost of an outpatient prescription drug generated by a rebate  
17 without first reducing the cost of the outpatient prescription drug to the  
18 patient to zero dollars.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>October 1, 2020</i>	New section

**Statement of Purpose:**

To require pharmacies to make manufacturers' rebates for prescription drugs available to patients.

*[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]*